clinical trial · NCT04551963
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
BeiGene·phase1·completed·n = 26
B-cell MalignanciesZanubrutinibFluconazoleDiltiazemVoriconazoleClarithromycin
brief summary
The primary objective of this study was to assess the steady-state zanubrutinib pharmacokinetics (PK) when co-administered with moderate and strong cytochrome P450 family 3 subfamily A (CYP3A) inhibitors.
started
Nov 15, 2020
primary completion
Feb 21, 2022
completion
Feb 21, 2022
last updated
Oct 26, 2024
official title
A Drug-Drug Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-Cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol